About Lantern Pharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lanternpharma.com/
Frequently Asked Questions
What is the 52-week range for LTRN?
The 52-week high is $4.7034 and the 52-week low is $0.8375.
What is the P/E ratio for LTRN?
The P/E ratio data is currently unavailable.
What is the dividend yield for LTRN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -198.35%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.19.
Analyst Recommendation Trends
Wall Street analyst consensus for LTRN over the last few months:
Latest LTRN News
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
DALLAS, September 30, 2026--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards by
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
DALLAS, September 29, 2026--Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern", the "Company" or "we"), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share (or pre-funded warrant in lieu thereof) i
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p. ET broadcast reaching audiences across the United States, Latin America and MENANEW YORK CITY, NY / ACCESS Newswire / September 26, 2026 / , the financial-media platform for public companies, pre-IPO companies and entrepreneurs, today announced that Show 773 will air tonight at 6:30 p.
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow
2026-09-24. The following slide deck was published by Lantern Pharma Inc.
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development September 23, 2026...
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
DALLAS, September 23, 2026--Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmark
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
DALLAS, September 22, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP‑284 to treat patients with mantle cell lymphoma
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
Lantern Pharma (NASDAQ:LTRN) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
DALLAS, September 17, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeu
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
October 3 Southeast Asia launch will add distribution reaching approximately 68 million householdsNEW YORK CITY, NY / ACCESS Newswire / September 5, 2026 / , the 18-year media brand serving public companies and companies aspiring to enter the public markets, today announced its latest broadcast airing at 6:30 PM ET across Bloomberg Television in the United States, Latin America and the Middle East and North Africa (MENA).The program features executive interviews and corporate updates from Lanter
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-12 | Schalop Lee Troy | -48,544 | - | - |
| 2026-05-12 | Schalop Lee Troy | +48,544 | $2.06 | $100,001 |
| 2026-05-12 | KEYSER D JEFFREY | -48,544 | - | - |
| 2026-05-12 | KEYSER D JEFFREY | +48,544 | $2.06 | $100,001 |
| 2026-01-09 | Silberstein David S. | +17,307 | - | - |
| 2026-01-09 | Silberstein David S. | +25,000 | - | - |
| 2026-01-09 | Schalop Lee Troy | +18,460 | - | - |
| 2026-01-09 | Schalop Lee Troy | +25,000 | - | - |
| 2026-01-09 | Chandru Vijay | +17,307 | - | - |
| 2026-01-09 | Chandru Vijay | +25,000 | - | - |
| 2026-01-09 | KEYSER D JEFFREY | +28,844 | - | - |
| 2026-01-09 | KEYSER D JEFFREY | +25,000 | - | - |
| 2026-01-09 | Maccecchini Maria-Luisa | +21,152 | - | - |
| 2026-01-09 | Maccecchini Maria-Luisa | +25,000 | - | - |
| 2025-12-18 | Margrave David R. | +20,000 | - | - |
| 2025-12-18 | Bhatia Kishor G. | +10,000 | - | - |